Journal of Neuroimmunology · 2017 · 12 citations · 36 references
Life SciencesImmunologyNeuroscienceImmunotherapyInflammationNeuroimmunologyAutoimmune DiseasesAutoimmune InflammationAutoimmune Neurological DisordersNeuroinflammationPeripheral Nerve InjuryPeripheral Nervous System ImmunityAutoimmune NeuropathologyAutoimmune Peripheral NeuropathiesBlood-tissue Barrier PermeabilityImmune-mediated NeuritisImmunomodulatory EffectsIntrathecal AdministrationPeripheral Nerve AutoimmunityPeripheral Nerve Inflammation
Intravenous human immunoglobulins dominate in the treatment of autoimmune neuropathies. We introduce intrathecal application as a new option for experimental autoimmune neuritis in Lewis rats. After immunisation with neuritogenic P2 peptide, we show a therapeutic and preventive effect of intrathecal human immunoglobulins (5-40mg/kg) on clinical and electrophysiological neuritis signs. Histology corroborated a lower degree of inflammation, demyelination, ICAM-1-dependent blood-nerve-barrier permeability and complement activation in the sciatic nerve. After preventive application, immunoglobulins induced a Th2 cytokine shift in the peripheral nerves already before clinical neuritis signs. Intrathecal immunoglobulin application could be a novel immunomodulatory option for autoimmune neuropathies.
36
HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD
Paul Imbach, V. D’Apuzzo, Andreas Hirt et al. · The Lancet · 1981 · 1.7K citations
Medicine, Hematology, Pediatrics +4
Ogden C. Bruton · PEDIATRICS · 1952 · 1.4K citations